SS-31 Peptide Research: Spinal Cord Injury Recovery

Every year, hundreds of thousands of people worldwide sustain spinal cord injuries (SCI), many facing permanent neurological deficits with limited therapeutic options. A growing body of research is exploring how peptide-based compounds might intervene in the cascade of cellular damage that follows SCI — and a newly published preclinical study is drawing significant attention. Published in Neurochemistry International (May 2026), research by Song, Ban, Zhao, and colleagues investigated whether the mitochondria-targeting peptide elamipretide, also known as SS-31, could improve outcomes after spinal cord injury in a mouse model. The findings suggest this peptide may support neurological recovery through multiple protective mechanisms at the cellular level.

What This Study Found

Spinal cord injury does not cause damage in a single event. The initial trauma — often called the primary injury — is followed by a prolonged wave of secondary damage driven by mitochondrial dysfunction, oxidative stress, and programmed cell death (apoptosis). This secondary injury cascade is a major reason why neurological deficits worsen in the hours, days, and weeks after the original trauma. It is also why researchers have been searching for compounds that can interrupt this process at the cellular level.

In this study, researchers used a mouse thoracic contusion model — a well-established laboratory method that mimics the type of blunt-force spinal cord damage commonly seen in human injuries. Mice that received SS-31 treatment demonstrated significantly enhanced locomotor recovery and gait performance compared to untreated controls, the study reports. Histological analyses — meaning direct examination of tissue samples — revealed reduced lesion pathology and greater preservation of neurons in the injured spinal cord region.

The researchers found that SS-31 appeared to act through several distinct but complementary pathways. In the early phase after injury, SS-31 treatment was associated with reduced markers of apoptosis, including decreased levels of cleaved caspase-3 and Bax — both proteins associated with cell death signaling — alongside increased levels of Bcl-2, a protein that promotes cell survival.

At the chronic stage of injury, the study found that SS-31-treated animals showed diminished astrogliosis — the excessive scarring response by glial cells that can form a physical barrier to nerve regeneration — as well as enhanced markers of axonal and synaptic remodeling, suggesting the neural circuitry was better able to reorganize and potentially compensate for the injury.

To better understand the cellular mechanisms, the researchers also studied SS-31's effects on PC12 cells — a widely used neuronal cell line — under conditions of oxidative stress. In these laboratory (in vitro) experiments, SS-31 was found to preserve mitochondrial membrane potential, reduce the accumulation of reactive oxygen species (ROS), and support the integrity of proteins involved in oxidative phosphorylation, the process by which mitochondria generate cellular energy. The study suggests that maintaining this energy-producing capacity may be central to SS-31's neuroprotective effects.

It is important to note that this research was conducted in animal models and cell cultures. As the authors acknowledge, these findings are preclinical, and human clinical data will be necessary to determine whether these effects translate to people with spinal cord injuries.

Clinical Significance

The significance of this research lies in its targeting of a biological process that has historically been difficult to address therapeutically. Mitochondrial dysfunction is not unique to spinal cord injury — it is a common driver of secondary damage in traumatic brain injury, stroke, and neurodegenerative diseases. A peptide capable of preserving mitochondrial function in the acute phase of neural injury could theoretically have broad clinical relevance, though researchers emphasize that translation from animal models to human patients requires extensive additional study.

What makes SS-31 particularly noteworthy in the research context is its mechanism of action. Unlike many antioxidant compounds that work systemically, SS-31 is designed to concentrate specifically within the inner mitochondrial membrane — the precise site where energy production occurs and where oxidative damage is most destructive after injury. This targeted approach is thought to explain why the peptide may be more effective at preserving mitochondrial function than broader antioxidant strategies that have shown limited success in clinical trials for neurological injury.

The study's finding that SS-31 reduced astrogliosis at the chronic stage is also clinically meaningful. Glial scarring is one of the primary obstacles to axonal regeneration after SCI, and any intervention that may reduce this barrier — even modestly — is considered significant by researchers working in this field. The observation of enhanced synaptic remodeling markers further suggests that the peptide may support the nervous system's intrinsic capacity for adaptation and plasticity.

Current Access and Compliance Context

Elamipretide (SS-31) is an investigational compound. It is not currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of spinal cord injury or any neurological condition. The peptide has been evaluated in human clinical trials for other indications — including heart failure and mitochondrial myopathy — but its use in SCI remains at the preclinical stage of research.

In the United States and many other countries, peptides like SS-31 may be available through compounding pharmacies under the supervision of a licensed physician. However, availability, regulatory status, and legal frameworks for compounded peptides vary significantly by jurisdiction and are subject to change. Individuals interested in peptide therapies should always consult with a qualified, licensed healthcare provider who can assess their specific medical situation and ensure any treatment is pursued within the appropriate legal and medical framework.

The Peptide Association supports responsible, evidence-informed access to peptide therapies under proper medical supervision. We encourage anyone interested in this area of research to work with a knowledgeable clinician rather than pursuing unregulated sources.

What Patients Should Know

For patients living with spinal cord injury or for families navigating a recent SCI diagnosis, research like this offers a measured but meaningful reason for cautious optimism. The study suggests that targeting mitochondrial dysfunction — particularly in the acute phase after injury — may be a viable strategy for limiting secondary neurological damage, though this has not yet been proven in human clinical trials.

Patients should be aware of several important points when evaluating research of this nature. First, results in mouse models do not always replicate in human studies. The biology of spinal cord injury is complex, and many compounds that showed promise in animal research have not demonstrated the same benefits when studied in people. Second, the optimal dosing, timing, and delivery route for SS-31 in humans — particularly in the acute post-injury window — have not been established. Third, as with any investigational compound, potential risks and side effects in human populations require thorough clinical evaluation.

That said, this study adds to a growing body of preclinical evidence supporting the investigation of mitochondria-targeting peptides as a therapeutic strategy in neurotrauma. Patients interested in staying informed about clinical trials involving SS-31 or similar compounds can search ClinicalTrials.gov for registered studies and speak with their neurologist or rehabilitation specialist about emerging treatment options.

Conclusion

The research by Song, Ban, Zhao, and colleagues represents a meaningful contribution to our understanding of how peptide-based interventions might one day support recovery after spinal cord injury. By targeting mitochondrial dysfunction, reducing apoptosis, limiting glial scarring, and supporting neural remodeling, SS-31 demonstrated multi-faceted neuroprotective effects in preclinical models. While human studies are needed before any clinical conclusions can be drawn, this research highlights the growing importance of mitochondria-targeted peptides in the field of neurotrauma.

If you are interested in learning more about peptide therapies and connecting with a qualified healthcare provider who stays current with emerging research, visit peptideassociation.org/find-a-doctor to find a knowledgeable clinician in your area.

---

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The research discussed is preclinical in nature; findings in animal models and cell cultures may not translate to human outcomes. Always consult a qualified, licensed healthcare provider before making any decisions regarding medical treatments or therapies. The Peptide Association does not endorse any specific treatment protocol or product.

---

Citation (AMA Format): Song Z, Ban Z, Zhao H, et al. Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury. Neurochem Int. 2026;106171. doi:10.1016/j.neuint.2026.106171. PMID: 42082001.